The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access) since our March 2023 update.
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework...
On March 18, 2024, Fresenius Kabi ("Fresenius") and Formycon announced a settlement agreement with Johnson & Johnson regarding FYB202, a proposed ustekinumab biosimilar to STELARA in Europe and Canada.
The key to success in a birth injury case is proving liability. Liability has two essential elements: a breach of the standard of care and causation. Where the allegation is that a newborn...
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.